Forward Therapeutics CEO Toufike Kanouni (L) and CSO Ewan Taylor

For­ward Ther­a­peu­tics, the first biotech from Curie.Bio, rais­es $50M for oral small mol­e­cules in im­munol­o­gy

An 18-month-old Flori­da biotech has raised a $50 mil­lion Se­ries A to wade in­to the hot im­munol­o­gy and in­flam­ma­tion (I&I) field with oral small mol­e­cules.

For­ward Ther­a­peu­tics un­veiled the fi­nanc­ing from BVF Part­ners, RA Cap­i­tal Man­age­ment and Or­biMed on Wednes­day morn­ing. The start­up will use the funds to gath­er Phase I da­ta with­in three years for its lead drug can­di­date, CEO Toufike Ka­nouni told End­points News.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.